thymalin: the Khavinson thymic peptide and what the literature shows

thymalin is a polypeptide preparation isolated from calf thymus and developed by Vladimir Khavinson and colleagues at the Military Medical Academy in Leningrad. it is a mixture of low-molecular-weight peptides rather than a single sequence, registered in Russia as an immunomodulator and used there for decades. the synthetic short-peptide analog of the active fragment is the dipeptide Glu-Trp, separately marketed as thymogen. Western randomized controlled trial evidence is limited, and this page treats that gap honestly.

what is thymalin?

thymalin is a peptide complex extracted from calf thymus and one of the earliest products of the Khavinson cytomedin program. it is a mixture rather than a single peptide, which is part of why its mechanism has been hard to characterize cleanly.

the Khavinson group began the cytomedin program at the Military Medical Academy in Leningrad in the 1970s and used a fractionation procedure on calf thymus to isolate a low-molecular-weight peptide preparation they called thymalin. the preparation contains peptides in the rough mass range of 1 to 10 kDa, dominated by smaller fragments thought to influence T-lymphocyte differentiation [1]. the group later identified what they considered the active fragment as the dipeptide Glu-Trp and registered the synthetic dipeptide separately as thymogen. so thymalin and thymogen are mechanistically related members of the same family: thymalin is the original tissue-derived mixture and thymogen is the simplified synthetic dipeptide analog.

how is thymalin supposed to work?

thymalin is proposed to act on T-lymphocyte maturation and on the broader cytokine balance of the immune system. the proposed mechanism is similar in spirit to other thymus-derived peptides, including the Western-developed thymosin family.

the Khavinson group describes thymalin as a regulator of T-cell differentiation, with reported effects on the ratio of helper to suppressor T-cells, on the expression of T-cell surface markers, and on cytokine production by stimulated lymphocytes [2]. the proposed downstream effect is correction of immune imbalance in conditions where T-cell function is depressed, including aging-related immunosenescence, post-infectious states, and post-chemotherapy recovery.

the mechanistic framing places thymalin in conversation with the Western thymosin literature, in particular thymosin alpha-1, a defined 28-amino-acid peptide originally isolated from thymus fraction 5 by Allan Goldstein's group in the 1970s. the two arose in parallel research traditions and share thematic similarity but are chemically distinct.

what does the evidence actually show?

thymalin has a longer publication history than the shorter Khavinson peptides and has been studied in Russia in a range of clinical settings. the literature is dominated by reports from the originating group and Russian collaborators. there are no large independent Western randomized controlled trials.

in immune senescence and older adults, thymalin has been reported in Russian clinical work to restore T-cell subsets toward younger reference ranges and improve markers of cellular immune function over courses of injectable treatment [2]. more recently, the COVID-19 period saw a series of Russian reports on thymalin in older patients with severe disease, claiming improvements in inflammatory markers and clinical recovery in combination with standard care [3]. these reports are mostly open-label or compared against historical controls and were not picked up by the major international randomized trial platforms.

in oncology supportive care, thymalin has been studied as an adjunct in patients receiving chemotherapy or radiation, with reports of preserved leukocyte counts and reduced infection rates [4]. again, these are mostly small or non-randomized studies and have not been independently replicated in the West. the honest summary: thymalin has a longer history and somewhat richer literature than other Khavinson short peptides, but it sits in the same evidence-quality category and would not meet Western regulatory standards for a clinical claim.

regulatory status

thymalin is registered in Russia as a pharmaceutical immunomodulator and has been used there in clinical practice for decades. it is not approved by the FDA, the EMA, or any other major Western regulator.

the Russian regulatory path for thymalin is genuinely a drug registration rather than a supplement registration, which sets it apart slightly from the other short Khavinson peptides. the registration is supported by the dossier from the originating group and the long history of in-country use. outside Russia and a handful of neighboring markets, thymalin is treated as a research compound. a reader buying thymalin outside its registered footprint is buying a research-grade peptide preparation with no Western validated identity testing and no Western human safety dataset of the kind needed for a clinical claim.

where it fits

thymalin is the original tissue-derived member of the thymus arm of the Khavinson bioregulator program. the most useful comparisons are with its synthetic analog thymogen and with the Western-developed thymosin alpha-1.

within the Khavinson family, thymalin sits alongside epitalon, pinealon, livagen, and vesugen. all share the same originating program and the same evidence-quality limitations. thymalin is the oldest and most studied of the group, and the short dipeptide thymogen (Glu-Trp) is the synthetic abbreviation of its proposed active fragment.

the most informative outside comparison is with thymosin alpha-1, a defined 28-amino-acid peptide developed in the West with a substantial international clinical literature in chronic hepatitis B and C and supportive care. they are mechanistically related but evidentiarily different: thymosin alpha-1 has a much larger Western trial base, although neither is FDA approved in the United States. for a broader comparison with peptides that have RCT-grade evidence like tesamorelin and semaglutide, see our free peptides and your body module.